• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Black Titan Corporation

    10/7/25 1:55:09 PM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BTTC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Black Titan Corp

    (Name of Issuer)


    Ordinary Shares, par value $0.001

    (Title of Class of Securities)


    G1156E102

    (CUSIP Number)


    10/01/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G1156E102


    1Names of Reporting Persons

    The Sire Group Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    SEYCHELLES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,019,313.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,019,313.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,019,313.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    14.1 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    G1156E102


    1Names of Reporting Persons

    Jeffrey Chung
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,019,313.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,019,313.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,019,313.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    14.1 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Mr. Chung, as the sole shareholder and director of The Sire Group Ltd., the record owner of the shares reported on this page, has the power to direct the vote and disposition of the shares.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Black Titan Corp
    (b)Address of issuer's principal executive offices:

    Level 8, Unit 8-02, The Bousteador, 10, Jalan PJU 7/6, Mutiara Damansara, 47800 PJ, Selangor, N8 47800
    Item 2. 
    (a)Name of person filing:

    The Sire Group Ltd. ("Sire"); Jeffrey Chung ("Mr. Chung")
    (b)Address or principal business office or, if none, residence:

    Sire: No. 4, Franky Building, Providence Industrial Estate, Mahe, Seychelles; Mr. Chung, 10-1, Floor 10, Altitude 236 Condominium, Jalan Alam Damai, 56000 Kuala Lumpur, Wilayah Persekutuan, Malaysia
    (c)Citizenship:

    Sire: Republic of Seychelles; Mr. Chung: United States
    (d)Title of class of securities:

    Ordinary Shares, par value $0.001
    (e)CUSIP No.:

    G1156E102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1,019,313
    (b)Percent of class:

    14.1%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    1,019,313

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    1,019,313

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Sire Group Ltd.
     
    Signature:/s/ Jeffrey Chung
    Name/Title:Jeffrey Chung, Director
    Date:10/07/2025
     
    Jeffrey Chung
     
    Signature:/s/ Jeffrey Chung
    Name/Title:Jeffrey Chung
    Date:10/07/2025
    Exhibit Information

    Joint Filing Agreement

    Get the next $BTTC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTTC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BTTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Black Titan Corporation seeks to explore Long-Term Strategic Crypto Initiatives with potential Strategic Investments in Digital Currencies

    NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Black Titan Corporation. (NASDAQ:BTTC) (the "Company" or "Black Titan"), today announced plans to seek long-term strategic crypto initiatives with potential strategic investments in digital currencies. Black Titan is exploring the utilization of a digital currency holding strategy to invest in and capitalize on cryptocurrency opportunities. Black Titan is actively exploring additional investments to expand its portfolio through direct coin acquisitions, mining, and fintech-related mergers and acquisitions. Chay W. J., CEO of Black Titan, remarked, "The approach of leveraging debt, equity, and cash flow to build Crypto holdings has delivered stro

    10/6/25 4:15:00 PM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals, Inc. Announces Closing of Merger with Black Titan Corporation

    NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. ("Titan" or "TTNP") today announced the successful closing of its previously announced merger with Black Titan Corporation ("Black Titan") and TalenTec Sdn. Bhd. ("TalenTec"). Following the merger, the combined company's ordinary shares, $0.0001 par value per share, will trade on the Nasdaq stock exchange under the ticker symbol NASDAQ: BTTC. Pursuant to the Merger and Contribution and Share Exchange Agreement dated August 19, 2024, Titan has become a wholly owned subsidiary of Black Titan Corporation, effective as of October 1, 2025. As part of the transaction, each issued and outstanding share of Titan common stock

    10/3/25 5:26:00 PM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BTTC
    SEC Filings

    View All

    SEC Form 6-K filed by Black Titan Corporation

    6-K - Black Titan Corp (0002034400) (Filer)

    10/8/25 6:29:09 PM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Black Titan Corporation

    SCHEDULE 13G - Black Titan Corp (0002034400) (Subject)

    10/7/25 1:55:09 PM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 425 filed by Black Titan Corporation

    425 - Black Titan Corp (0002034400) (Subject)

    10/3/25 5:26:58 PM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care